Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
Clinical Summary
View sourceWhat was studied
Preclinical in vitro and ex vivo experiments tested a recombinant anti–Staphylococcus aureus endolysin (XZ.700) on patient-derived S. aureus growth, skin colonization (healthy and lesional CTCL skin), and S. aureus–driven malignant T‑cell activation/proliferation.
Key findings
XZ.700 cut S. aureus counts by ≥4-log CFU at ≥1 mg/mL within 1 hour and dropped SEA toxin from >15 ng/mL to <1 ng/mL at 4 hours; on skin, 1 µg/mL coaddition nearly prevented colonization and 10 µg/mL after colonization almost eradicated bacteria, while also suppressing S. aureus–induced IFNγ/CXCL10 and blocking CD25/pSTAT5 and Ki‑67 increases in malignant T cells in coculture.
Study limitations
Findings are limited to laboratory and ex vivo models with small human tissue samples (five lesional sites from three patients), using few bacterial isolates; several authors are affiliated with the endolysin’s developer.
Clinical implications
In CTCL models, targeted S. aureus killing with an endolysin curtailed skin colonization and halted S. aureus–driven malignant T‑cell activation, suggesting a potential nonantibiotic decolonization strategy that warrants clinical testing.
Related Questions
Explore related topics and deepen your understanding